Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free CHGCY Stock Alerts

Chugai Pharmaceutical (CHGCY) Stock Forecast & Price Target

Chugai Pharmaceutical logo
$21.55 -0.87 (-3.88%)
As of 08/14/2026 04:00 PM Eastern
Compare

Chugai Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy
Based on 4 Analyst Ratings
Sell
0
Hold
2
Buy
2

Based on 4 Wall Street analysts who have issued ratings for Chugai Pharmaceutical in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 2 have given a hold rating, 1 has given a buy rating, and 1 has given a strong buy rating for CHGCY.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for CHGCY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Chugai Pharmaceutical and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CHGCY Analyst Ratings Over Time

TypeCurrent Forecast
8/16/25 to 8/16/26		1 Month Ago
7/17/25 to 7/17/26		3 Months Ago
5/18/25 to 5/18/26		1 Year Ago
8/16/24 to 8/16/25
Strong Buy
1 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
 N/A
Buy
1 Buy rating(s)
1 Buy rating(s)
0 Buy rating(s)
 N/A
Hold
2 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
 N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
 N/A
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingModerate BuyBuyStrong BuyN/A

CHGCY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CHGCY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Chugai Pharmaceutical Stock vs. The Competition

TypeChugai PharmaceuticalHealthcare CompaniesBroader Market
Consensus Rating Score
2.75
2.30
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted UpsideN/A785.25% Upside11.05% Upside
News Sentiment Rating
Positive News

See Recent CHGCY News
Positive News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
8/6/2026
UBS Group AG logo
UBS Group
4 of 5 stars
 DowngradeStrong-Buy ➝ Hold
6/15/2026
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
3 of 5 stars
 UpgradeHold ➝ Buy
5/29/2026
Zacks Research logo
Zacks Research
5 of 5 stars
 UpgradeHold
2/25/2026
Smbc Nikko Sec. logo
Smbc Nikko Sec.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeStrong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:16 PM ET.


Should I Buy Chugai Pharmaceutical Stock? CHGCY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 10, 2026. Please send any questions or comments about these Chugai Pharmaceutical pros and cons to contact@marketbeat.com.

Chugai Pharmaceutical
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Chugai Pharmaceutical Co., Ltd.:

  • Chugai Pharmaceutical Co., Ltd. has a strong portfolio of oncology products, including the latest versions of Avastin and Tecentriq, which are widely used and have shown significant efficacy in treating various cancers.
  • The company is recognized for its research-driven approach, particularly in developing monoclonal antibodies, which are a growing segment in the biopharmaceutical market.
  • Chugai has strategic alliances with Roche Group, enhancing its research capabilities and market reach, which can lead to more innovative product offerings and increased revenue potential.
  • The current stock price is around $50, reflecting a stable position in the market, which may attract investors looking for reliable pharmaceutical stocks.
  • Chugai is actively developing new therapies in various fields, including immunology and neuroscience, indicating a commitment to innovation and potential for future growth.

Chugai Pharmaceutical
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Chugai Pharmaceutical Co., Ltd. for these reasons:

  • Despite its strong product lineup, Chugai faces intense competition in the biopharmaceutical sector, which could impact market share and pricing strategies.
  • The company’s reliance on a few key products for revenue could pose risks if any of these products face regulatory challenges or market saturation.
  • Chugai's stock performance may be influenced by broader market trends and economic conditions, which can lead to volatility in stock prices.
  • Investors should consider the potential for high research and development costs, which can affect profitability, especially if new products do not achieve expected market success.
  • As a subsidiary of Roche Holding Ltd., any strategic decisions made by the parent company could impact Chugai's operational independence and growth trajectory.

CHGCY Forecast - Frequently Asked Questions

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chugai Pharmaceutical in the last year. There are currently 2 hold ratings, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CHGCY shares.

According to analysts, Chugai Pharmaceutical's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Chugai Pharmaceutical's stock had 2 upgrades and 1 downgrade by analysts.

Chugai Pharmaceutical has been rated by research analysts at The Goldman Sachs Group, UBS Group, and Zacks Research in the past 90 days.

Analysts like Chugai Pharmaceutical more than other "healthcare" companies. The consensus rating for Chugai Pharmaceutical is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how CHGCY compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Chugai Pharmaceutical Recommendations


This page (OTCMKTS:CHGCY) was last updated on 8/16/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
A Dark Day Is Coming to America
Keith Kaplan, CEO of TradeSmith, has spent more than $17 million studying AI since 2022. He says a major shift...
TradeSmith | Sponsoredtc pixel
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
What is Trump’s decade-long obsession?
No president has moved markets like Trump, adding and erasing trillions in value seemingly at will. Analyst...
Brownstone Research | Sponsoredtc pixel